Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Seroba Life Sciences

Founders Peter Sandys

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 40
Average round size
info
The average size of a deal this fund participated in
$32M
Portfolio companies 26
Rounds per year 2.67
Lead investments 8
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.35
Exits 8
Key employees 4
Stages of investment
Early Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Medical Device
  • Therapeutics
Summary

The main department of described VC is located in the Dublin. The company was established in Europe in Ireland.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Seroba Life Sciences, startups are often financed by Imperial Innovations, Oxford Capital Partners, Nesta Ventures. The meaningful sponsors for the fund in investment in the same round are Enterprise Ireland, Inventages Venture Capital Investment Inc., Andera Partners. In the next rounds fund is usually obtained by Enterprise Ireland, Novartis Venture Fund, Roche Venture Fund.

The fund was created by Peter Sandys. The overall number of key employees were 4.

Among the most successful fund investment fields, there are Therapeutics, Medical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Ireland. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Fusion Pharmaceuticals, Atlantic Therapeutics, PQ Bypass. The fund has exact preference in some founders of portfolio startups.

The real fund results show that this VC is 11 percentage points more often commits exit comparing to other companies. The top activity for fund was in 2019. Opposing the other organizations, this Seroba Life Sciences works on 6 percentage points less the average amount of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2018. The fund is generally included in less than 2 deals every year.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Seroba Life Sciences:
Typical Co-investors
Seroba Life Sciences is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Seroba Life Sciences:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from Ireland
Funds with similar focus located in Ireland:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Shorla Pharma

Biotechnology
Pharmaceutical
$35M04 Oct 2023 Ireland, County Tipperary, Ireland

Complement Therapeutics

Biotechnology
Medical
$84M17 Apr 2023 London, England, United Kingdom

Deciphex

$4M25 Jan 2023 Dublin, County Dublin, Ireland

Storm Therapeutics

Biotechnology
Health Care
Medical
Therapeutics
$30M14 Dec 2022 Cambridge, England, United Kingdom

Sibylla Biotech

Biotechnology
Health Care
Medical
Pharmaceutical
$27M04 Oct 2022 Trento, Trentino-Alto Adige, Italy

Perfuze

Biotechnology
Health Care
Medical
Medical Device
$26M09 Feb 2022 Galway City, County Galway, Ireland

Coave Therapeutics

Biotechnology
$38M21 Jul 2021 Bretagne, Brittany, France

Palliare

$8M28 Jun 2021 Oceanside, California, United States

Shorla Pharma

Biotechnology
Pharmaceutical
$8M03 Jun 2020 Ireland, County Tipperary, Ireland
News
Coave Therapeutics Closes €33M in Series B Financing

– Coave Therapeutics, a Paris, France-based clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, raised a €21.2m ($25.1m) expansion of its Series B funding round, bringing the total raised to €33.1m ($39m).
– This round was led by Seroba Life Sciences, supported by new investors Théa Open Innovation and eureKARE alongside existing shareholders Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, and Sham Innovation Santé/Turenne.
– The company will use the proceeds to support the execution of its corporate strategy, which is focused on advancing its lead clinical program CTx-PDE6b for the treatment of PDE6b inherited retinal dystrophies, currently in Phase I/II clinical trial, towards pivotal trials, developing its AAV Ligand Conjugate (‘ALIGATER’) platform, which is designed to enhance the delivery and efficiency of AAV vectors via a proprietary chemical conjugation technology to produce targeted gene therapy products, advancing new preclinical programs, based on AAV-Ligand Conjugate capsids (coAAV), in rare CNS and Ocular diseases, including CTx-GBA1 for Parkinson’s disease and Gaucher Disease and CTx-ABCA4 for Stargardt’s disease, entering partnerships in key disease areas to progress novel coAAV candidates towards the clinic and to address other disease areas given the potential of the platform and the scope for targeting other tissues.

Palliare Closes $8M Series A Funding Round

– Palliare is a Galway, Ireland-based safe operating room company.
– The company closed an $8m Series A funding round led by Seroba Life Sciences with participation from SCM AD Ventures, Western Development Commission, and several private investors.
– The company intends to use the funds to support US commercial launch activities related to its EVA15 insufflator and smoke evacuation system, as well as new Research & Development activities.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Seroba Life Sciences?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 40
Average round size 32M
Rounds per year 2.67
Peak activity year 2019
Lead investments 8
Follow on index 0.35
Exits 8
Group Appearance index 0.95

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Shorla Pharma

Biotechnology
Pharmaceutical
$35M04 Oct 2023 Ireland, County Tipperary, Ireland

Complement Therapeutics

Biotechnology
Medical
$84M17 Apr 2023 London, England, United Kingdom

Deciphex

$4M25 Jan 2023 Dublin, County Dublin, Ireland

Storm Therapeutics

Biotechnology
Health Care
Medical
Therapeutics
$30M14 Dec 2022 Cambridge, England, United Kingdom

Sibylla Biotech

Biotechnology
Health Care
Medical
Pharmaceutical
$27M04 Oct 2022 Trento, Trentino-Alto Adige, Italy

Perfuze

Biotechnology
Health Care
Medical
Medical Device
$26M09 Feb 2022 Galway City, County Galway, Ireland

Coave Therapeutics

Biotechnology
$38M21 Jul 2021 Bretagne, Brittany, France

Palliare

$8M28 Jun 2021 Oceanside, California, United States

Shorla Pharma

Biotechnology
Pharmaceutical
$8M03 Jun 2020 Ireland, County Tipperary, Ireland
Crunchbase icon

Content report

The following text will be sent to our editors: